In Group II, the 2 female and 3 male patients had a mean age of 55 years (range 41-68) and a mean weight of 62 kg (range 42-83). They were studied while undergoing twice-weekly htmodialysis, using a single pass system with a 1 m2 multipoint Kiil dialyser and a Cuprophane membrane. They were also studied between dialysis.
In Group II, the 2 female and 3 male patients had a mean age of 55 years (range 41-68) and a mean weight of 62 kg (range 42-83). They were studied while undergoing twice-weekly htmodialysis, using a single pass system with a 1 m2 multipoint Kiil dialyser and a Cuprophane membrane. They were also studied between dialysis.
The procedure was identical to that for Group I, except that for patients connected to the dialyser the last blood sample taken was 8 h after injection. Only 2 patients micturated between dialyses and none during dialysis.
Several serum and urine samples from patients in Groups I and If were examined for the presence of possible metabolites of cefuroxime, using a high pressure liquid chromatography system (HPLC) under 3 different chromatographic conditions. The column was injected with undiluted serum and urine samples and also with cefuroxime and likely metabolites which had been extracted from the urines. The anti-isomer as well as the glycoxamido and hydroxime derivatives of cefuroxime as possible metabolites were prepared and used as reference standards in the system. The absorption peaks were detected by an ultraviolet detector at 273 nm.
Group III comprised a patient undergoing peritoneal dialysis. She was 57 years old, weighed 56 kg and suffered from bilateral pelviureteric obstruction. She did not void urine during the study. The procedure was identical to that for patients in Group II during hmmodialysis.
There were 2 patients in Group IV, both 65-year-old females with analgesic nephropathy, who developed asymptomatic urinary tract infections. A Klebsiella sp. was isolated from one patient who had a GFR of 6.9 ml/min and weighed 38 kg, and Proteus mirabilis from the other who had a GFR of 4.8 ml/min and weighed 46 kg. The 2 women were given 500 mg of cefuroxime i.m. once daily for 7 and 14 days respectively. Blood samples were taken before injection and 1 h afterwards on several occasions during treatment. Hmmatological and biochemical screening was carried out before the start of therapy and at the end.
All samples were stored at -20°C, pending assay. The concentrations of cefuroxime in serum and urine were measured by a large plate bioassay, using a spore suspension of Bacillus subtilis 1904E as assay organism and Oxoid Antibiotic Agar No. 2 with 0.3 % sodium citrate as medium.
The limit of detection of cefuroxime was 0.1 mg/l.
The serum half-life of the antibiotic in each patient was calculated by a graphical method and the amount of cefuroxime, and hence percentage of total dose excreted was determined from the appropriate measurements. The pharmacokinetics of cefuroxime in normal volunteers has been well documented (Foord 1976 , Goodwin et al. 1977 , Gower & Dash 1977 . Extensive studies in animals have shown that the compound has very low toxicity (Capel-Edwards et al. 1977) and published data (Sack & Wilhelm 1974 , Sack 1976 , Sack et al. 1977 ) further suggest that cefuroxime has a considerably lower nephrotoxic potential than other parenteral cephalosporins, any signs of nephrotoxicity manifesting themselves only at doses vastly higher than would be administered clinically.
In addition, the antibiotic has a wide antibacterial spectrum, possessing a strong resistance to attack by most P-lactamases (O'Callaghan et al. 1976 ) and an ability to penetrate rapidly to the site of infection. These properties suggest that cefuroxime may prove the ideal agent for patients with bacterial infections complicated by renal failure. Since the antibiotic is excreted almost exclusively by the kidneys, however, therapeutically adequate serum and urine concentrations will probably be obtained using a reduced dosage. In order to estimate the degree of any such reduction, the pharmacokinetics of cefuroxime have been studied in 4 groups of patients with chronic renal failure.
Patients and Methods There were 4 male and 4 female patients in the first group. The mean age was 57 years (range 41-68) and mean weight 62 kg (range 38-85 kg). Glomerular filtration rate (GFR), measured by 51Cr-labelled ethylenediamine-tetra-acetate (EDTA), lay between 4.8-82 ml/min. Four patients had a GFR<20 ml/min, 2 had a rate of 20-50 ml/min and EDTA clearance in one patient was 82 ml/min.
A single bolus injection of 500 mg of cefuroxime was administered i.v. to each patient and venous blood samples were taken immediately preceding injection and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h afterwards. The pre-injection and 24 h samples underwent extensive haematological and biochemical screening.
Urine was collected at 0-2, 2-4, 4-6, 6-8, 8-12 and 12-24 h after injection and the volumes of urine passed for each period recorded.
RESULTS

Patients not Requiring Dialysis
Patients not requiring dialysis had serum concentrations which followed a biphasic pattern, the steeper slope of the early part of the curve being largely caused by distribution into the tissues, whereas the latter part was associated with excretion of the antibiotic. The mean and ranges of the serum concentrations for Group I can be seen in Fig 1. The concentrations were similar soon after injection in both the sub-groups with poorer renal function. The patient with EDTA clearance of 82 ml/min had a three-fold lower serum level at 0.5 h. At 4 h the concentration was twice as high in the sub-group with EDTA clearance of <20 ml/min as in that with clearance of 20-50 ml/min and 4 times as high as for the patient with GFR of 82 ml/min. At 6 h this differential had increased.
By 24 h the concentration in both sub-groups with GFR >20 ml/min had fallen to zero but a mean level of 10.3 mg/l was found in the serum of patients with a clearance of < 20 ml/min.
The serum half-life measured from the latter part of the curve progressively increased from 1.8 h when EDTA clearance was 82 ml/min to 16.1 h with a clearance of 4.8 ml/min. The mean urine concentrations for each subgroup are shown in Table 1 . Mean excretion as a percentage of the dose of cefuroxime can be seen in The mean serum half-life between dialyses was 15.2 h (range 9.2-22.5) and on the Kiil dialyser 3.3 h (range 2.3-4.2).
Only 2 of the patients passed urine between dialyses and none during dialysis. Specimens of urine were therefore pooled into 0-2, 2-6, and 6-24 h periods. The individual concentrations and urinary recoveries as a percentage of the dose are presented in Table 2 . None of the serum samples and only one of the urine samples showed the presence of a substance which on HPLC behaved in a manner similar to 100r Urinary Excretion of Cefuroxime as z of dose Serum concentration lJJg/ml I Table 2 Individual urine concentrations and recoveries of cefuroxime in 2 patients between dialyses that of one of the reference standards. This sample had been obtained 2-6 h after injection in a patient studied between hemodialyses. The retention time on the column corresponded to the hydroxime derivative of cefuroxime (i.e. demethylation of the methoxime group). The size of the peak was about 2% of that of the unchanged cefuroxime in that sample (i.e. about 80 ,ug/l compared with 441 mg/i). There were no other metabolites identified (J Ayrton, K J Child & G Harnbypersonal communication).
Patient on Peritoneal Dialysis
The serum concentrations of this patient, who did not void any urine during the period of study can be seen in Table 3 . The serum half-life was estimated at 5.4 h which might be expected from a patient with a GFR of about 15 ml/min. Infections  Fig 4 shows injections of500 mg ofcefuroxime uLI cefuroxime and there were no side-effects although both experienced minor, transient pain after some of the injections. There were no adverse effects on hematological or biochemical indices, with these nor with any of the patients studied.
Patients with Urinary Tract
Discussion and Conclusions
The serum half-life of cefuroxime after i.v. bolus injection in normal subjects is 1.1 h (Foord 1976 , Gower & Dash 1977 . This value and the mean half-life from patients on dialysis, as well as individual results from patients not requiring dialysis are plotted in Fig 5. The relationship between serum half-life and renal function is clearly seen. It would appear that the effect of the Kiil dialyser on cefuroxime excretion is equivalent to a GFR of about 27 ml/min (range 22-37). This is similar to the 25 ml/min found with cephalexin (Bailey et al. 1970) . These data suggest that with severe or moderately severe renal failure, accumulation of cefuroxime may occur at high dosage.
Adequate therapeutic blood levels occur in patients on dialysis given 500 mg once daily, although a further 500 mg would be required at the end of each dialysis. A single daily dose of 500 mg should be with the lower GFR. Peak concentrations were consistent likewise but they were higher in the patient with the better renal function. The higher peaks in this patient may be partly explained by her smaller body weight compared with the first. Nine days after the end of the one week of treatment, Klebsiella was again isolated from the urine. It was still sensitive to cefuroxime. In the other patient, the Proteus mirabilis was not isolated after 2 weeks of treatment. Neither patient showed evidence of progressive accumulation of Cefuroxime adequate in patients with GFRs of < 10 ml/min, and this was confirmed by the studies in the 2 patients receiving repeated doses. With clearances between 10 and 20 ml/min, a dose of 500 mg twice daily should be adequate, as should 500 mg every 8 h for those patients with clearances of 20-50 ml/min. When renal function is >50 ml/ min, no reduction from normal dosage seems necessary. Further studies of blood levels after repeated doses in patients with various degrees of impaired renal functions are required to confirm these suggestions. Concentrations of cefuroxime in the urine of patients not requiring hkmodialysis appear therapeutically sufficient. This is indicated by the response of the 2 patients with asymptomatic bacteriuria, both of whom had very severe chronic renal failure.
Summary
The pharmacokinetics of cefuroxime have been studied in four groups of patients with chronic renal failure. Group I consisted of patients who did not require dialysis and Group I1 of patients receiving regular hemodialysis (these were studied on and between dialyses). Group III was given peritoneal dialysis and Group IV had urinary tract infections necessitating therapy for 1-2 weeks. Groups I-IIL were given a 500 mg bolus dose of cefuroxime i.v. Serum and urine concentrations were measured at intervals. When GFRs were between 20 and 50 ml/min, the serum half-life ranged from 1.8-3.4 b; when <20 ml/min the serum half-life was 6.1-22.5 h. With a GFR >50 ml/min, the serum half-life was 1.8 h. The Kiil hmmodialyser reduced the serum half-life to an average of 3.1 h and peritoneal dialysis to 5.4 h. Cefuroxime was not metabolized to any significant extent and was excreted in the urine in adequate concentrations. The rate of excretion was inversely related to the degree of renal failure. Studies in Group IV patients added support to the following dosage modifications: adults on dialysis, 500 mg daily plus 500 mg at the end of dialysis; EDTA clearances of < 10 ml/min, 500 mg daily; EDTA clearances of 10-20 ml/min 500 mg twice daily; EDTA clearances of 20-50 ml/min, 500 mg thrice daily. With EDTA clearances of >50 ml/min, no modification of the normal recommended dosage is required. some of his patients, particularly the last one, were somewhat lighter than others he had dealt with, which might account for some differences.
Dr L D Sabath (Minneapolis) said that Dr Gower's last patient, the one showing considerably greater EDTA clearance, nonetheless showed lower levels. Dr Gower agreed. The effect might be partly explicable because of the patient's small size. He felt that EDTA clearance rates themselves were accurate to within the order of 0.1 ml/min, although he could not be precise about their reproducibility.
In answer to the Chairman, he said that the flow rates of blood and dialysis fluid had been maintained very uniformly. Flow rates could hardly account for the differences.
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Dr R Rangoonwala (Frankfurt) asked Dr Kosmidis for the half-life value of his patient on peritoneal dialysis. Dr Kosmidis said that on dialysis the figure was 9-16 h; off dialysis it was 22 h. He did not know what factors, rehydration for example, accounted for this rather low figure.
Dr Neu (Chairman), in summary, said that speakers had demonstrated the excellent safety of the compound in an animal model of pyelonephritis and also its great efficacy in pyelonephritis in the rat. Clearly they needed more data about hemodialysis and peritoneal dialysis levels. It would also be valuable to have data on greater numbers of osteomyelitis patients especially with organisms which have in the past been treated with aminoglycosides with only limited success.
